Pacira BioSciences Reports Third Quarter 2021 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Pacira BioSciences Reports Third Quarter 2021 Financial Results

Pacira Pharmaceuticals (PCRX) PT Raised to $62 at BMO Capital

November 5, 2021 6:49 AM EDT

BMO Capital analyst Gary Nachman raised the price target on Pacira Pharmaceuticals (NASDAQ: PCRX) to $62.00 (from $60.00) while maintaining a Market Perform rating.

The analyst commented, "3Q Exparel sales preannounced 10/11 had been weaker-than-expected from continued COVID headwinds, but PCRX's optimistic in recovering procedure trends... More

Pacira Pharma (PCRX) Tops Q3 EPS by 7c

November 3, 2021 8:06 AM EDT

Pacira Pharma (NASDAQ: PCRX) reported Q3 EPS of $0.72, $0.07 better than the analyst estimate of $0.65. Revenue for the quarter came in at $127.7 million versus the consensus estimate of $130.38 million.

For earnings history and earnings-related data on Pacira Pharma (PCRX) click here.

... More